Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) is a biopharmaceutical company focused on rare hematology diseases and rare diseases of the immune system, with a core emphasis on CXCR4‑targeted therapies. Its news flow frequently centers on the development and commercialization of mavorixafor, an orally available CXCR4 antagonist marketed in the United States as XOLREMDI® in its first indication and under active investigation in chronic neutropenia and other rare hematologic conditions.
On this page, readers can review news items that X4 has issued about its clinical, corporate and financial milestones. These include updates on the global, pivotal Phase 3 4WARD trial in chronic neutropenia, where mavorixafor is being evaluated as an oral, once‑daily therapy with or without G‑CSF in people with congenital, acquired primary autoimmune, or idiopathic chronic neutropenia who experience recurrent and serious infections. News coverage also highlights Phase 2 trial data demonstrating durable increases in absolute neutrophil count, reductions or discontinuation of injectable G‑CSF in many participants, and safety observations consistent with previous mavorixafor studies.
Investors and observers will also find press releases on financing transactions such as private placements of common stock and pre‑funded warrants, underwritten public offerings, and an equity purchase agreement with Lincoln Park Capital Fund, LLC. These announcements describe how X4 intends to fund the pivotal development of mavorixafor in chronic neutropenia and support its commercialization activities. Additional news items cover organizational restructuring, workforce reductions, leadership and board changes, and participation in healthcare and hematology conferences where X4 presents clinical data and corporate updates.
By following XFOR news, readers can track how X4 Pharmaceuticals reports progress in its rare hematology programs, interprets emerging clinical results for mavorixafor, and manages its capital structure and operations as it advances its CXCR4‑based therapeutic strategy.
X4 Pharmaceuticals issued inducement awards to new employees under the 2019 Inducement Equity Incentive Plan on March 31, 2023. The awards included options for an aggregate of 595,000 shares of common stock with an exercise price of $0.87 per share, matching the closing stock price on the grant date. These options will vest over four years, with 25% vesting after the first year and the remainder monthly thereafter, contingent on continued employment. X4 is advancing its lead candidate, mavorixafor, aimed at treating chronic neutropenic disorders, and is preparing for a U.S. regulatory submission.
X4 Pharmaceuticals (Nasdaq: XFOR) reported its financial results for Q4 and FY 2022, with a net loss of $29.1 million for Q4 and $93.9 million for the full year. Despite the losses, the company highlighted the successful Phase 3 results for mavorixafor, achieving its primary endpoints in WHIM syndrome trials. Upcoming milestones include additional Phase 3 data presentation in Q2 2023, an NDA submission in early H2 2023, and a potential U.S. launch in H1 2024. X4's strong cash position of $123 million supports operations through Q2 2024, fueled by recent financings totaling $120 million.
X4 Pharmaceuticals (Nasdaq: XFOR) announced it will report its financial results for the fourth quarter and full year ending December 31, 2022, on March 21, 2023. A conference call will follow at 9:00 a.m. ET to discuss these results and recent business highlights. X4 is focused on developing mavorixafor, a novel therapy for chronic neutropenic disorders, including WHIM syndrome. The company is preparing for a U.S. regulatory submission after positive Phase 3 trial results. The investor webcast will be available on X4's website post-call.
X4 Pharmaceuticals (Nasdaq: XFOR) announced the issuance of inducement awards for new employees, totaling 54,900 options to purchase common stock at an exercise price of $0.94 per share. These awards, granted under the 2019 Inducement Equity Incentive Plan, were approved by the board's compensation committee and are part of Nasdaq Listing Rule 5635(c)(4). The options vest over four years, with 25% vesting after one year. X4 focuses on developing therapies for immune system diseases, with its lead candidate mavorixafor showing promise in treating WHIM syndrome, currently preparing for a U.S. regulatory submission after positive Phase 3 trial results.
X4 Pharmaceuticals has announced positive developments regarding its clinical candidate mavorixafor for treating chronic neutropenic disorders. Highlights from the Phase 1b clinical trial presented at the American Society of Hematology meeting indicate that a single oral dose significantly increased absolute neutrophil count (ANC) across all participants, with overall good tolerance. The company also revealed that between 37,000–48,000 people in the U.S. have chronic neutropenia, emphasizing the substantial unmet medical needs in this patient population.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) announced a public offering of 52.3 million shares, including pre-funded warrants for 6.8 million shares, alongside Class C warrants for 29.55 million shares, priced at $1.10 each. The offering aims to raise approximately $65 million, or up to $74.8 million if the underwriters' option is exercised. The offering is expected to close on December 9, 2022. Piper Sandler, Stifel, and Cantor are the joint book-running managers. The offering is filed under a shelf registration statement with the SEC.
X4 Pharmaceuticals (Nasdaq: XFOR) has announced an underwritten public offering of its common stock and accompanying warrants. The offering, conducted by Piper Sandler, Stifel, and Cantor, includes a 30-day option for underwriters to purchase additional shares. The offering's completion is subject to market conditions, and no assurance is provided regarding the final terms. X4 is focused on developing mavorixafor, a treatment for immune system diseases, particularly chronic neutropenic disorders.
X4 Pharmaceuticals announced positive top-line results from its Phase 3 clinical trial (4WHIM) of mavorixafor for WHIM syndrome. The trial met its primary endpoint, demonstrating clinical superiority over placebo in increasing absolute neutrophil counts (P < 0.0001) and absolute lymphocyte counts (P < 0.0001). Mavorixafor was well tolerated, with no serious adverse events reported. Following the trial, over 90% of participants chose to continue treatment, highlighting its potential. The company aims to meet U.S. regulatory authorities in early 2023 for further steps towards regulatory approval.
X4 Pharmaceuticals (Nasdaq: XFOR) announced management's participation in a fireside chat at the Stifel Healthcare Conference on November 15, 2022, at 3:00 PM ET. The event will be streamed live on their website, with an archive available for 90 days post-event. X4 Pharmaceuticals focuses on novel therapies for immune system diseases, including their leading candidate, mavorixafor, a small-molecule therapy targeting CXCR4, currently in global Phase 3 trials for WHIM syndrome.
Scorpion Therapeutics has announced the formation of a Clinical Scientific Advisory Board (Clinical SAB) to enhance its Precision Oncology 2.0 strategy. This board comprises esteemed physician-scientists specialized in cancer treatment and development. The Clinical SAB will provide insights to expedite the company's lead programs, including STX-478 and STX-721, aimed at advancing toward investigational new drug applications in 2023. CEO Axel Hoos expressed optimism about the expertise of the members and their potential impact on improving cancer therapies.
FAQ
What is the current stock price of X4 Pharmaceuticals (XFOR)?
What is the market cap of X4 Pharmaceuticals (XFOR)?
